MedPath

Nimotuzumab

Generic Name
Nimotuzumab
Drug Type
Biotech
CAS Number
780758-10-3
Unique Ingredient Identifier
6NS400BXKH

Overview

No overview information available.

Background

No background information available.

Indication

Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.

Associated Conditions

  • Advanced Head and Neck Cancer
  • Advanced Stage Head and Neck Cancer
  • Glioblastoma Multiforme (GBM)
  • High Grade Glioma (HGG)
  • Advanced Epithelial Tumor of the Head and Neck

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
2025/05/25
NCT06988956
Phase 2
Recruiting
The First Affiliated Hospital with Nanjing Medical University
AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer
2025/04/22
NCT06938503
Phase 2
Not yet recruiting
Tianjin Medical University Cancer Institute and Hospital
TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
2025/04/06
NCT06912711
Phase 2
Recruiting
Sun Yat-sen University
HRS-4642 Combined with Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma
2025/03/25
NCT06773130
Phase 1
Recruiting
West China Hospital
A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma
2025/03/17
NCT06879691
Phase 4
Active, not recruiting
Biotech Pharmaceutical Co., Ltd.
Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma
2025/01/17
NCT06781073
Phase 3
Completed
Biotech Pharmaceutical Co., Ltd.
Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer
2025/01/17
NCT06781086
Phase 2
Not yet recruiting
Biotech Pharmaceutical Co., Ltd.
Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix
2025/01/13
NCT06771596
Phase 2
Active, not recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
HRS-4642 with Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
2025/01/13
NCT06770452
Phase 2
Not yet recruiting
Zhejiang University
Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
2024/12/09
NCT06722911
Phase 2
Recruiting
Zhejiang Provincial People's Hospital

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Nimotuzumab Injection
百泰生物药业有限公司
国药准字S20080001
生物制品
注射剂
11/28/2022

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy